Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malaria,Falciparum | Biological: R21/Matrix-M Biological: ChAd63/MVA ME-TRAP Biological: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge | Phase 2 |
A total of 64 participants will be enrolled for challenge and divided into four groups as follows:
Blood tests and clinical assessments will be conducted to screen out participants with health conditions that may impact participation in the study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 64 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety, Immunogenicity, and Efficacy of R21/Matrix-M and ChAd63/MVA-ME-TRAP in the Context of Controlled Human Malaria Infection: A Phase IIb Trial in Kenyan Adults |
Estimated Study Start Date : | April 2021 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | January 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Group 1
Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
|
Biological: R21/Matrix-M
R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
Biological: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
|
Experimental: Group 2
Group 2 adults (n=20) will be receiving 5x10^10 vp ChAd63 ME-TRAP and 2x10^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
|
Biological: ChAd63/MVA ME-TRAP
ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
Biological: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
|
Experimental: Group 3
Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
|
Biological: R21/Matrix-M
R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
Biological: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
|
Experimental: Group 4
Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
|
Biological: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
|
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Rachel Roberts | +44 (0)1865 611418 | vaccinetrials@ndm.ox.ac.uk |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | May 7, 2019 | ||||
First Posted Date ICMJE | May 13, 2019 | ||||
Last Update Posted Date | February 4, 2021 | ||||
Estimated Study Start Date ICMJE | April 2021 | ||||
Estimated Primary Completion Date | January 2023 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults | ||||
Official Title ICMJE | Safety, Immunogenicity, and Efficacy of R21/Matrix-M and ChAd63/MVA-ME-TRAP in the Context of Controlled Human Malaria Infection: A Phase IIb Trial in Kenyan Adults | ||||
Brief Summary | This is a phase IIb clinical trial in malaria-exposed individuals to assess the immunogenicity, safety and efficacy of the two vaccines in the context of controlled human malaria infection, P. falciparum sporozoite challenge (PfSPZ Challenge). | ||||
Detailed Description |
A total of 64 participants will be enrolled for challenge and divided into four groups as follows:
Blood tests and clinical assessments will be conducted to screen out participants with health conditions that may impact participation in the study. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Malaria,Falciparum | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Not yet recruiting | ||||
Estimated Enrollment ICMJE |
64 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | January 2023 | ||||
Estimated Primary Completion Date | January 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years to 45 Years (Adult) | ||||
Accepts Healthy Volunteers ICMJE | Yes | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | Not Provided | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03947190 | ||||
Other Study ID Numbers ICMJE | VAC074 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | University of Oxford | ||||
Study Sponsor ICMJE | University of Oxford | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE | Not Provided | ||||
PRS Account | University of Oxford | ||||
Verification Date | February 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |